Latest Recce Pharmaceuticals (ASX:RCE) News

Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.

Recce Pharmaceuticals reports strong Phase II results for its RECCE® 327 topical gel, achieving a 93% efficacy rate in treating serious skin infections and setting the stage for accelerated Phase 3 trials.

Recce Pharmaceuticals has temporarily paused trading of its securities, signaling a potentially significant development pending further disclosure.

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.

Recce Pharmaceuticals has successfully dosed all patients in its Phase II trial of RECCE® 327 topical gel for acute bacterial skin infections, showing encouraging preliminary efficacy and safety data. The company is preparing for pivotal Phase III trials in Australia and Indonesia, targeting a significant global market opportunity.